Adherence & Retention
Using mean corpuscular volume (MCV) to assess drug exposure
Dear All,
Any recommended reports on how to use MCV to assess drug exposure?
I am aware of 2 articles discussed the MCV result (Kamya, MR et.al., 2007) or recommending it as part of a formula but was not described (Herrmann, S et.al., 2007) and its original reference was a poster presentation (Herrmann S, et.al. 2004).
Any tips?
Best regards
ziad
- Kamya, MR et.al., JAIDS, Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. 2007.
- Herrmann, S et.al. Intern Med J. Evidence-based, multifactorial approach to addressing non-adherence to antiretroviral therapy and improving standards of care. 2007.
- Herrmann S, McKinnon E, Mallal S. Combining Adherence Monitoring with Patient Education in the Royal Perth Hospital Immunology Outpatient Clinic. 16th Annual Conference of the Australasian Society for HIV Medicine; 2–4 September 2004.
Canberra, Australia. Oral presentation. Published by the Australasian Society for HIV medicine, Darlinghurst, NSW, Australia. 2004.
David Bangsberg, MD, MPH
Dear Ziad,
The best paper I know of this subject suggest that a normal MCV confirms adherence below 70%, but a elevated MCV does not confirm adherence above 70% to AZT or D4T. Citation, below.
Best,
David
Int J STD AIDS. 2002 Nov;13(11):748-54.
Mean cell volume (MCV) changes in HIV-positive patients taking nucleoside reverse
transcriptase inhibitors (NRTIs): a surrogate marker for adherence.
Steele RH, Keogh GL, Quin J, Fernando SL, Stojkova V.
9:27 AM, 26 Oct 2008 | Permalink